To address the growing global health challenge of obesity, the World Health Organization has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.
Obesity, which affects more than 1 billion people, was associated with 3.7 million deaths worldwide in 2024, according to WHO. Without decisive action, the number of people with obesity is projected to double by 2030.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com